Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
Acquired resistance to immunomodulatory drugs is common in multiple myeloma patients, but rarely attributed to genetic alterations. Here, proteomic, phosphoproteomic and RNA sequencing analysis in five paired pre-treatment and relapse samples reveals a CDK6-regulated protein resistance signature.
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-02-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-022-28515-1 |
| _version_ | 1818501238999744512 |
|---|---|
| author | Yuen Lam Dora Ng Evelyn Ramberger Stephan R. Bohl Anna Dolnik Christian Steinebach Theresia Conrad Sina Müller Oliver Popp Miriam Kull Mohamed Haji Michael Gütschow Hartmut Döhner Wolfgang Walther Ulrich Keller Lars Bullinger Philipp Mertins Jan Krönke |
| author_facet | Yuen Lam Dora Ng Evelyn Ramberger Stephan R. Bohl Anna Dolnik Christian Steinebach Theresia Conrad Sina Müller Oliver Popp Miriam Kull Mohamed Haji Michael Gütschow Hartmut Döhner Wolfgang Walther Ulrich Keller Lars Bullinger Philipp Mertins Jan Krönke |
| author_sort | Yuen Lam Dora Ng |
| collection | DOAJ |
| description | Acquired resistance to immunomodulatory drugs is common in multiple myeloma patients, but rarely attributed to genetic alterations. Here, proteomic, phosphoproteomic and RNA sequencing analysis in five paired pre-treatment and relapse samples reveals a CDK6-regulated protein resistance signature. |
| first_indexed | 2024-12-10T20:53:27Z |
| format | Article |
| id | doaj.art-d4504678ee754ca4b1b981178e24fb56 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-10T20:53:27Z |
| publishDate | 2022-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-d4504678ee754ca4b1b981178e24fb562022-12-22T01:34:02ZengNature PortfolioNature Communications2041-17232022-02-0113111310.1038/s41467-022-28515-1Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myelomaYuen Lam Dora Ng0Evelyn Ramberger1Stephan R. Bohl2Anna Dolnik3Christian Steinebach4Theresia Conrad5Sina Müller6Oliver Popp7Miriam Kull8Mohamed Haji9Michael Gütschow10Hartmut Döhner11Wolfgang Walther12Ulrich Keller13Lars Bullinger14Philipp Mertins15Jan Krönke16Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinDepartment of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinDepartment of Internal Medicine III, Ulm University HospitalDepartment of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinDepartment of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of BonnExperimentelle Pharmakologie & Onkologie (EPO) Berlin-Buch GmbHDepartment of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinProteomics Platform, Max Delbrück Center for Molecular MedicineDepartment of Internal Medicine III, Ulm University HospitalProteomics Platform, Max Delbrück Center for Molecular MedicineDepartment of Pharmaceutical & Medicinal Chemistry, Pharmaceutical Institute, University of BonnDepartment of Internal Medicine III, Ulm University HospitalExperimental and Clinical Research Center, Charité Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular MedicineDepartment of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinDepartment of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinProteomics Platform, Max Delbrück Center for Molecular MedicineDepartment of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu BerlinAcquired resistance to immunomodulatory drugs is common in multiple myeloma patients, but rarely attributed to genetic alterations. Here, proteomic, phosphoproteomic and RNA sequencing analysis in five paired pre-treatment and relapse samples reveals a CDK6-regulated protein resistance signature.https://doi.org/10.1038/s41467-022-28515-1 |
| spellingShingle | Yuen Lam Dora Ng Evelyn Ramberger Stephan R. Bohl Anna Dolnik Christian Steinebach Theresia Conrad Sina Müller Oliver Popp Miriam Kull Mohamed Haji Michael Gütschow Hartmut Döhner Wolfgang Walther Ulrich Keller Lars Bullinger Philipp Mertins Jan Krönke Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma Nature Communications |
| title | Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma |
| title_full | Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma |
| title_fullStr | Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma |
| title_full_unstemmed | Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma |
| title_short | Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma |
| title_sort | proteomic profiling reveals cdk6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma |
| url | https://doi.org/10.1038/s41467-022-28515-1 |
| work_keys_str_mv | AT yuenlamdorang proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT evelynramberger proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT stephanrbohl proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT annadolnik proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT christiansteinebach proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT theresiaconrad proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT sinamuller proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT oliverpopp proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT miriamkull proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT mohamedhaji proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT michaelgutschow proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT hartmutdohner proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT wolfgangwalther proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT ulrichkeller proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT larsbullinger proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT philippmertins proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma AT jankronke proteomicprofilingrevealscdk6upregulationasatargetableresistancemechanismforlenalidomideinmultiplemyeloma |